Psychophysiological stress: A significant parameter in drug pharmacokinetics

Expert Opinion on Drug Metabolism and Toxicology

Volumn 9, Issue 10, 2013, Pages 1317-1334

  Konstandi, Maria ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Cytochrome; Drug metabolism; Liver; Pharmacokinetics; Psychophysiological stress

Indexed keywords

ADRENALIN; AMFEBUTAMONE; CHLORZOXAZONE; COUMARIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 1A; CYTOCHROME P450 2A; CYTOCHROME P450 2B; CYTOCHROME P450 2C; CYTOCHROME P450 2D; CYTOCHROME P450 2E1; DEXAMETHASONE; DRUG METABOLIZING ENZYME; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KETAMINE; LOSARTAN; NICOTINE; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN; OMEPRAZOLE; PACLITAXEL; PARACETAMOL; PIOGLITAZONE; PROPOFOL; RIFAMPICIN; TAMOXIFEN; UNINDEXED DRUG; WARFARIN;

DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; GENE EXPRESSION; GENETIC POLYMORPHISM; HUMAN; MENTAL STRESS; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PHYSICAL STRESS; REVIEW; SEX;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DISEASE MODELS, ANIMAL; DOWN-REGULATION; DRUG INTERACTIONS; HUMANS; LIVER; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; STRESS, PHYSIOLOGICAL; STRESS, PSYCHOLOGICAL; UP-REGULATION;

EID: 84884259330     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2013.816283     Document Type: Review

References (159)

1. Sheiner LB, Steimer JL. Pharmacokinetic/pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol 2000;40:67-95
2. Waller DG, Renwick AG, Hillier K. Pharmacokinetics. In: Horne T, Kenner H, editors, Medical pharmacology and therapeutics. Elsevier, Saunders, Edinburgh, UK; 2005. p. 17
3. Gonzalez FJ, Gelboin HV. Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab Rev 1994;26:165-83
4. Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: The past, present and future. Trends Pharmacol Sci 2004a;25(4):193-200
5. Ingelman-Sundberg M. Human drug metabolising cytochrome P450 enzymes: Properties and polymorphisms. Naunyn Schmiedebergs Arch Pharmacol 2004b;369:89-104
6. Matamoros RA, Levine BS. Stress response and drug metabolism in mice. Fund Appl Toxicol 1996;30(2):255-63
7. Konstandi M, Johnson EO, Marselos M, et al. Stress-mediated modulation of B (alpha)P-induced hepatic CYP1A1: Role of catecholamines. Chem Biol Interact 2004;147:65-77
8. Konstandi M, Marselos M, Radon-Camus AM, et al. The role of stress in the regulation of drug metabolizing enzymes in mice. Eur J Drug Metab Pharmacokinet 1998;23:483-90
9. Konstandi M, Johnson E, Lang MA, et al. Stress modulates the enzymatic inducibility by benzo[alpha]pyrene in the rat liver. Pharmacol Res 2000;42:205-11
10. Daskalopoulos EP, Malliou F, Rentesi G, et al. Stress is a critical player in CYP3A, CYP2C, and CYP2D regulation: Role of adrenergic receptor signaling pathways. Am J Physiol Endocrinol Metab 2012;303(1):E40-54
11. Guengerich FP. Cytochrome p450 and chemical toxicology. Chem Res Toxicol 2008;21(1):70-83
12. Nebert DW, Roe AL, Dieter MZ, et al. Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control, and apoptosis. Biochem Pharmacol 2000;59(1):65-85
13. Pelkonen O, Nebert DW. Metabolism of polycyclic aromatic hydrocarbons: Etiologic role in carcinogenesis. Pharmacol Rev 1982;34(2):189-222
14. Park GR. Molecular mechanisms of drug metabolism in the critically ill. Br J Anaesth 1996;77:32-49
15. Gonzalez FJ. Role of cytochromes P450 in chemical toxicity and oxidative stress: Studies with CYP2E1. Mutat Res 2005;569(1-2):101-10
16. Danielson PB. The cytochrome P450 superfamily: Biochemistry, evolution and drug metabolism in humans. Curr Drug Metab 2002;3(6):561-97
17. Sigel R, Sigel A, Sigel H. The ubiquitous roles of cytochrome P450 proteins: Metal ions in life sciences. Wiley; New York: 2007. ISBN 0-470-01672-8
18. Nelson DR. The cytochrome P450 homepage. Hum Genomics 2009;4:59-65
19. Chen CS, Lin JT, Goss KA, et al. Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: Identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics. Mol Pharmacol 2004;65(5):1278-85
20. Available from: Http://drnelson.uthsc.edu/human.P450.table.html 21. Ingelman-Sundberg M. The human genome project and novel aspects of cytochrome P450 research. Toxicol Appl Pharmacol 2005;207:52-6
21. Ortiz de Montellano PR. Cytochrome P450: Structure, mechanism, and biochemistry. Kluwer Academic/Plenum Publishers; New York: 2005
22. Guengerich FP. Cytochromes P450, drugs, and diseases. Mol Interv 2003;3:194-204
23. Gonzalez FJ. The molecular biology of cytochrome P450s. Pharmacol Rev 1988;40(4):243-88
24. Wislocki PG, Gadek KM, Chou MW, et al. Carcinogenicity and mutagenicity of the 3,4-dihydrodiols and other metabolites of 7,12-dimethylbenz(a) anthracene and its hydroxymethyl derivatives. Cancer Res 1980;40(10):3661-4
25. Guengerich FP, MacDonald TL. Mechanisms of cytochrome P-450 catalysis. FASEB J 1990;4(8):2453-9
26. Guengerich FP. Molecular advances for the cytochrome P-450 superfamily. Trends Pharmacol Sci 1991;12(8):281-3
27. Hollenberg PF. Mechanisms of cytochrome P450 and peroxidasecatalyzed xenobiotic metabolism. FASEB J 1992;6(2):686-94
28. Rendic S, Guengerich FP. Update information on drug metabolism systems-2009, part II: Summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters. Curr Drug Metab 2010;11(1):4-84
29. Cheng PY, Morgan ET. Hepatic cytochrome P450 regulation in disease states. Curr Drug Metab 2001;2(2):165-83
30. Johnson EO, Kamilaris TC, Chrousos GP, Gold PW. Mechanisms of stress: A dynamic overview of hormonal and behavioral homeostasis. Neurosci Biobehav Rev 1992;16(2):115-30
31. Chrousos GP, Kino T. Glucocorticoid signaling in the cell. Expanding clinical implications to complex human behavioral and somatic disorders. Ann NY Acad Sci 2009;1179:153-66
32. Chrousos GP, Gold PW. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA 1992;267(9):1244-52. Presents the involvement of stress in the pathophysiology of various disease states
33. Dipple A. Formation, metabolism, and mechanism of action of polycyclic aromatic hydrocarbons. Cancer Res 1983;43(5 Suppl):2422s-5s
34. Sugimura T, Sato S. Mutagens-carcinogens in foods. Cancer Res 1983;43(5 Suppl):2415s-21s
35. Guengerich FP. Comparisons of catalytic selectivity of cytochrome P450 subfamily enzymes from different species. Chem Biol Interact 1997;106(3):161-82
36. Martignoni M, de Kanter R, Grossi P, et al. An in vivo and in vitro comparison of CYP induction in rat liver and intestine using slices and quantitative RT-PCR. Chem Biol Interact 2004;151:1-11
37. Shimada T, Mimura M, Inoue K, et al. Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans. Arch Toxicol 1997;71(6):401-8
38. Choudhary D, Jansson I, Stoilov I, et al. Expression patterns of mouse and human CYP orthologs (families 1-4) during development and in different adult tissues. Arch Biochem Biophys 2005;436(1):50-61
39. McDonnell WM, Scheiman JM, Traber PG. Induction of cytochrome P450IA genes (CYP1A) by omeprazole in the human alimentary tract. Gastroenterology 1992;103(5):1509-16
40. Zhang W, Parentau H, Greenly RL, et al. Effect of protein-calorie malnutrition on cytochromes P450 and glutathione S-transferase. Eur J Drug Metab Pharmacokinet 1999;24(2):141-7
41. Kawajiri K. Chapter 15. CYP1A1. Volume 148 IARC Sci Publications, Chichester, UK; 1999. p. 159-72
42. Cheng PY, Morgan ET. Hepatic cytochrome P450 regulation in disease states. Curr Drug Metab 2001;2(2):165-83
43. Shimada T, Fujii-Kuriyama Y. Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1. Cancer Sci 2004;95(1):1-6
44. Roymans D, Annaert P, Van Houdt J, et al. Expression and induction potential of cytochromes P450 in human cryopreserved hepatocytes. Drug Metab Dispos 2005;33(7):1004-16
45. Shou M, Krausz KW, Gonzalez FJ, Gelboin HV. Metabolic activation of the potent carcinogen dibenzo[a,l]pyrene by human recombinant cytochromes P450, lung and liver microsomes. Carcinogenesis 1996;17(11):2429-33
46. Newton DJ, Wang RW, Lu AY; Cytochrome P450 Inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 1995;23(1):154-8
47. Shimada T, Yamazaki H, Foroozesh M, et al. Selectivity of polycyclic inhibitors for human cytochrome P450s 1A1, 1A2, and 1B1. Chem Res Toxicol 1998;11:1048-56
48. Kobayashi K, Urashima K, Shimada N, Chiba K. Selectivities of human cytochrome P450 inhibitors toward rat P450 isoforms: Study with cDNA-expressed systems of the rat. Drug Metab Dispos 2003;31:833-6
49. Okey AB. Enzyme induction in the cytochrome P-450 system. Pharmacol Ther 1990;45(2):241-98
50. Haduch A, Wojcikowski J, Daniel WA. Effect of short- and long-term treatment with antidepressant drugs on the activity of rat CYP2A in the liver. Pharmacol Rep 2005;57:774-81
51. Robottom-Ferreira AB, Aquino SR, Queiroga R, et al. Expression of CYP2A3 mRNA and its regulation by 3-methylcholanthrene, pyrazole, and beta-ionone in rat tissues. Braz J Med Biol Res 2003;36:839-44
52. Su T, Ding X. Regulation of the cytochrome P450 2A genes. Toxicol Appl Pharmacol 2004;199:285-94
53. Honkakoski P, Negishi M. The structure, function, and regulation of cytochrome P450 2A enzymes. Drug Metab Rev 1997;29(4):977-96
54. Pelkonen O, Rautio A, Raunio H, Pasanen M. CYP2A6: A human coumarin 7-hydroxylase. Toxicology 2000;144:139-47
55. Konstandi M, Lang MA. Effect of cocaine on hepatic drug metabolism. Eur J Int Med 1996;7:221-6
56. Martignoni M, Groothuis GM, de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2006;2(6):875-94
57. Czerwinski M, McLemore TL, Gelboin HV, Gonzalez FJ. Quantification of CYP2B7, CYP4B1, and CYPOR messenger RNAs in normal human lung and lung tumors. Cancer Res 1994;54:1085-91
58. Xie W, Evans RM. Orphan nuclear receptors: The exotics of xenobiotics. J Biol Chem 2001;276:37739-42
59. Lang T, Klein K, Fischer J, et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 2001;11:399-415
60. Honkakoski P, Sueyoshi T, Negishi M. Drug-activated nuclear receptors CAR and PXR. Ann Med 2003;35:172-82
61. Martignoni M, Groothuis GM, de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2006;2(6):875-94
62. Vignati LA, Bogni A, Grossi P, Monshouwer M. A human and mouse pregnane X receptor reporter gene assay in combination with cytotoxicity measurements as a tool to evaluate species-specific CYP3A induction. Toxicology 2004;199:23-33
63. Bogaards JJ, Bertrand M, Jackson P, et al. Determining the best animal model for human cytochrome P450 activities: A comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 2000;30:1131-52
64. Park SH, Liu X, Hennighausen L, et al. Distinctive roles of STAT5a and STAT5b in sexual dimorphism of hepatic P450 gene expression. Impact of STAT5a gene disruption. J Biol Chem 1999;274(11):7421-30
65. Honkakoski P, Kojo A, Lang MA. Regulation of the mouse liver cytochrome P450 2B subfamily by sex hormones and phenobarbital. Biochem J 1992;285(3):979-83
66. Weaver RJ, Thompson S, Smith G, et al. A comparative study of constitutive and induced alkoxyresorufin O-dealkylation and individual cytochrome P450 forms in cynomolgus monkey (Macaca fascicularis), human, mouse, rat and hamster liver microsomes. Biochem Pharmacol 1994;47(5):763-73
67. Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 2009;41(2):89-295
68. Dai Y, Rashba-Step J, Cederbaum AI. Stable expression of human cytochrome P4502E1 in HepG2 cells: Characterization of catalytic activities and production of reactive oxygen intermediates. Biochemistry 1993;32:6928-37
69. Zuber R, Anzenbacherova E, Anzenbacher P. Cytochromes P450 and experimental models of drug metabolism. J Cell Mol Med 2002;6:189-98
70. Niznik HB, Tyndale RF, Sallee FR, et al. The dopamine transporter and cytochrome P45OIID1 (debrisoquine 4-hydroxylase) in brain: Resolution and identification of two distinct [3H]GBR-12935 binding proteins. Arch Biochem Biophys 1990;276:424-32
71. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: Overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004;369(1):23-37
72. Novak RF, Woodcroft KJ. The alcohol-inducible form of cytochrome P450 (CYP 2E1):role in toxicology and regulation of expression. Arch Pharm Res 2000;23:267-82
73. Salaspuro MP, Lieber CS. Non-uniformity of blood ethanol elimination: Its exaggeration after chronic consumption. Ann Clin Res 1978;10:294-7
74. Wu D, Cederbaum AI. Alcohol, oxidative stress, and free radical damage. Alcohol Res Health 2003;27:277-84
75. Ohashi Y, Yamada K, Takemoto I, et al. Inhibition of human cytochrome P450 2E1 by halogenated anilines, phenols, and thiophenols. Biol Pharm Bull 2005;28:1221-3
76. Spatzenegger M, Jaeger W. Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metab Rev 1995;27(3):397-417. The clinical dimension of the CYP-catalysed drug metabolism is presented
77. Liu YT, Hao HP, Liu CX, et al. Drugs as CYP3A probes, inducers, and inhibitors. Drug Metab Rev 2007;39(4):699-721. Presents the numerous drugs that are substrates, inducers or inhibitors of CYP3A, one of the most important CYPs in drug metabolism in humans
78. Pelkonen O, Raunio H. Metabolic activation of toxins: Tissue-specific expression and metabolism in target organs. Environ Health Perspect 1997;105(Suppl4):767-74
79. Shimada T, Guengerich FP. Evidence for cytochrome P-450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver. Proc Natl Acad Sci USA 1989;86(2):462-5
80. Zhou SF, Xue CC, Yu XQ, et al. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 2007;29(6):687-710
81. Burk O, Wojnowski L. Cytochrome P450 3A and their regulation. Naunyn Schmiedebergs Arch Pharmacol 2004;369(1):105-24
82. Ma J, Graves J, Bradbury JA, et al. Regulation of mouse renal CYP2J5 expression by sex hormones. Mol Pharmacol 2004;65(3):730-43
83. Konstandi M, Cheng J, Gonzalez FJ. Sex steroid hormones regulate constitutive expression of Cyp2e1 in female mouse liver. Am J Physiol Endocrinol Metab 2013;304(10):E1118-28
84. Wiwi CA, Waxman DJ. Role of hepatocyte nuclear factors in growth hormone-regulated, sexually dimorphic expression of liver cytochromes P450. Growth Factors 2004;22(2):79-88
85. Waxman DJ, Pampori NA, Ram PA, et al. Interpulse interval in circulating growth hormone patterns regulates sexually dimorphic expression of hepatic cytochrome P450. Proc Natl Acad Sci USA 1991;88(15):6868-72
86. Pampori NA, Shapiro BH. Gender differences in the responsiveness of the sex-dependent isoforms of hepatic P450 to the feminine plasma growth hormone profile. Endocrinology 1999;140(3):1245-54
87. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007;116(3):496-526
88. Stranger BE, Forrest MS, Dunning M, et al. Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science 2007;315:848-53
89. Zhou SF, Liu JP, Lai XS. Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development. Curr Med Chem 2009a;16(21):2661-805
90. Zhou SF, Zhou ZW, Yang LP, Cai JP. Substrates, inducers, inhibitors and structure-activity relationships of human cytochrome P450 2C9 and implications in drug development. Curr Med Chem 2009b;16(27):3480-675
91. Nebert DW, Jones JE. Regulation of the mammalian cytochrome P1-450 (CYP1A1) gene. Int J Biochem 1989;21(3):243-52
92. Ioannides C, Parke DV. The cytochrome P450 I gene family of microsomal hemoproteins and their role in the metabolic activation of chemicals. Drug Metab Rev 1990;22(1):1-85
93. Whitlock JP Jr, Okino ST, Dong L, et al. Cytochromes P450 5: Induction of cytochrome P4501A1: A model for analyzing mammalian gene transcription. FASEB J 1996;10(8):809-18
94. Pelkonen O, Nebert DW. Metabolism of polycyclic aromatic hydrocarbons: Etiologic role in carcinogenesis. Pharmacol Rev 1982;34(2):189-222
95. Vuppugalla R, Shah RB, Chimalakonda AP, et al. Microsomal cytochrome P450 levels and activities of isolated rat livers perfused with albumin. Pharm Res 2003;20(1):81-8
96. Parkinson A, Mudra DR, Johnson C, et al. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 2004;199(3):193-209
97. Kim SK, Novak RF. The role of intracellular signaling in insulin-mediated regulation of drug metabolizing enzyme gene and protein expression. Pharmacol Ther 2007;113(1):88-120 AKT signal transduction pathway in CYP regulation
98. Kotsovolou O, Ingelman-Sundberg M, Lang MA, et al. Hepatic drug metabolizing profile of Flinders Sensitive Line rat model of depression. Prog Neuropsychopharmacol Biol Psychiatry 2010;34(6):1075-84
99. Waxman DJ, O'Connor C. Growth hormone regulation of sex-dependent liver gene expression. Mol Endocrinol 2006;20(11):2613-29
100. Hodgson E, Rose RL. Metabolic interactions of agrochemicals in humans. Pest Manag Sci 2008;64(6):617-21
101. Pelkonen O, Turpeinen M, Hakkola J, et al. Inhibition and induction of human cytochrome P450 enzymes: Current status. Arch Toxicol 2008;82(10):667-715
102. Waxman DJ, Holloway MG. Sex differences in the expression of hepatic drug metabolizing enzymes. Mol Pharmacol 2009;76(2):215-28
103. Chrousos GP. Stress and disorders of the stress system. Nat Rev Endocrinol 2009;5:374-81
104. Levine S, Goldman L, Coover GD. Expectancy and the pituitary-adrenal system. In: Porter R, Knight J, editors, Physiology, emotion and psychosomatic illness. CIBA Foundation Symposium 8. Elsevier/Excerpta Medica; Amsterdam: 1972. p. 281-91
105. Mason JW. A review of psychoendocrine research on the sympatho-adrenal medullary system. Psychosom Med 1968;30:576-607
106. Selye H. Stress. The physiology and pathophysiology of exposure to stress. Acta; Montreal: 1950
107. Aguilera G. Corticotropin releasing factor receptors: Characterization and actions in the anterior pituitary gland. In: Chrousos GP, Loriaux DL, Gold PW, editors. Mechanisms of physical and emotional stress. Advances in experimental medicine and biology Volume 245 Plenum Press; New York: 1988. p. 83-105
108. File SE, Clarke A. Exploration motor activity after intraventricular ACTH, morphine and naloxone. Behav Brain Res 1980;2:223-7
109. Bernardini R, Kamilaris TC, Calogero AE, et al. Interactions between tumor necrosis factor-a, hypothalamic corticotropin-releasing hormone and adrenocorticotropin secretion in the rat. Endocrinology 1990;126:2876-81
110. Bird SJ, Kuhar MJ. Iontophoretic application of opiates to the locus ceruleus. Brain Res 1977;122:523-33
111. Kvetnansky R, Sabban EL, Palkovits M. Catecholaminergic systems in stress: Structural and molecular genetic approaches. Physiol Rev 2009;89:535-606
112. Selye H. A syndrome produced by diverse nocuous agents. Nature 1936;138:32
113. Yates E, Marsh D, Maran J. The adrenal cortex. In: Mountcastle V, editor. Medical physiology. 14th edition. CV. Mosby, St. Louis; 1980. p. 1558-601
114. Krieger D. Cushing's syndrome. Monographs in endocrinology. Volume 22 Springer-Verlag; Berlin: 1982
115. Tsigos C, Chrousos GP. Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J Psychosom Res 2002;53:865-71. Presents the major effectors of the stress response
116. Blalock JE. A molecular basis for bidirectional communication between the immune and neuroendocrine systems. Physiol Rev 1989;69:1-32
117. Sapolsky R, Krey LC, McEwen BS. The neuroendocrinology of stress and aging: The glucocorticoid cascade hypothesis. Endocr Rev 1986;7:284-301
118. Broadhurst PL. Experiments in psychogenetics applications of biomedical genetics to the inheritance of behavior. In: Eysenck HJ, editor. Experiments in personality psychogenetics and psychopharmacology. Volume 1 Routledge and Keegan Paul, London; 1960. p. 1-102
119. Money J. The syndrome of abuse dwarfism (psychosocial dwarfism or reversible hyposomatotropinism): Behavioral data and case report. Am J Dis Child 1977;131:508-13
120. Money J, Annecillo C, Kelley JF. Abuse-dwarfism syndrome: After rescue, statural and intellectual catchup growth correlate. J Clin Child Psychol 1983;12:279-83
121. Weigent DA, Blalock JE. Interactions between the neuroendocrine and immune systems: Common hormones and receptors. Immunol Rev 1987;100:79-100
122. Antonia K, Anastasia A, Tesseromatis C. Stress can affect drug pharmacokinetics via serum/tissues protein binding and blood flow rate alterations. Eur J Drug Metab Pharmacokinet 2012;37(1):1-7
123. Peng HT, Cheung B. A review of psychophysiological stressors on pharmacokinetics. J Clin Pharmacol 2011;51(11):1499-518
124. Flaten MA, Asli O, Simonsen T. The effect of stress on absorption of acetaminophen. Psychopharmacology (Berl) 2006;185(4):471-8
125. Breslin FC, Hayward M, Baum A. Effect of stress on perceived intoxication and the blood alcohol curve in men and women. Health Psychol 1994;13(6):479-87
126. Jamali F, Kunz-Dober CM. Pain-mediated altered absorption and metabolism of ibuprofen: An explanation for decreased serum enantiomer concentration after dental surgery. Br J Clin Pharmacol 1999;47(4):391-6
127. Gianaros PJ, Quigley KS, Mordkoff JT, Stern RM. Gastric myoelectrical and autonomic cardiac reactivity to laboratory stressors. Psychophysiology 2001;38(4):642-52
128. Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: Basic principles and practical applications. Br J Clin Pharmacol 2004;57(1):6-14
129. Peckett AJ, Wright DC, Riddell MC. The effects of glucocorticoids on adipose tissue lipid metabolism. Metabolism 2011;60(11):1500-10
130. Pervanidou P, Chrousos GP. Metabolic consequences of stress during childhood and adolescence. Metabolism 2012;61(5):611-19
131. Konstandi M, Lang MA, Kostakis D, et al. Predominant role of peripheral catecholamines in the stress-induced modulation of CYP1A2 inducibility by benzo(alpha)pyrene. Basic Clin Pharmacol Toxicol 2008;02:35-44
132. Konstandi M, Johnson E, Lang MA, et al. Noradrenaline, dopamine, serotonin: Different effects of psychological stress on brain biogenic amines in mice and rats. Pharmacol Res 2000;41(3):341-6
133. Konstandi M, Kostakis D, Harkitis P, et al. Benzo(alpha)pyrene-induced up-regulation of CYP1A2 gene expression: Role of adrenoceptor-linked signaling pathways. Life Sci 2006;79:331-41
134. Flint MS, Hood BL, Sun M, et al. Proteomic analysis of the murine liver in response to a combined exposure to psychological stress and 7,12- dimethylbenz(a)anthracene. J Proteome Res 2010;9(1):509-20
135. Zordoky BN, El-Kadi AO. Role of NF-kappaB in the regulation of cytochrome P450 enzymes. Curr Drug Metab 2009;10(2):164-78
136. Kennedy JM, Riji AM. Effects of surgery on the pharmacokinetic parameters of drugs. Clin Pharmacokinet 1998;35(4):293-312
137. Chen QM, Alexander D, Sun H, et al. Corticosteroids inhibit cell death induced by doxorubicin in cardiomyocytes: Induction of antiapoptosis, antioxidant, and detoxification genes. Mol Pharmacol 2005;67(6):1861-73
138. Lee MY, Clark JE, Williams DE. Induction of flavin-containing monooxygenase (FMO B) in rabbit lung and kidney by sex steroids and glucocorticoids. Arch Biochem Biophys 1993;302(2):332-6
139. Bonamassa B, Ma Y, Liu D. Glucocorticoid receptor-mediated transcriptional regulation of N-acetyltransferase 1 gene through distal promoter. AAPS J 2012;14(3):581-90
140. Sugatani J, Nishitani S, Yamakawa K, et al. Transcriptional regulation of human UGT1A1 gene expression: Activated glucocorticoid receptor enhances constitutive androstane receptor/pregnane X receptor-mediated UDP-glucuronosyltransferase 1A1 regulation with glucocorticoid receptor-interacting protein 1. Mol Pharmacol 2005;67(3):845-55
141. Bian HS, Ngo SY, Tan W, et al. Induction of human sulfotransferase 1A3 (SULT1A3) by glucocorticoids. Life Sci 2007;81(25-26):1659-67
142. Horsfield BP, Reidy GF, Murray M. Studies on the developmental and adrenal regulation of cytosolic and microsomal epoxide hydrolase activities in rat liver. Biochem Pharmacol 1992;44(4):815-18
143. Ding X, Lichti K, Kim I, et al. Regulation of constitutive androstane receptor and its target genes by fasting, cAMP, hepatocyte nuclear factor alpha, and the coactivator peroxisome proliferator-activated receptor gamma coactivator-1alpha. J Biol Chem 2006;281(36):26540-51
144. Kolesnichenko LS, KulinskiA - VI, Ias'ko MV, et al. Effect of insulin and adrenaline on the activity of enzymes of glutathione metabolism and glutathione concentration in rat organs. Probl Endokrinol (Mosk) 1994;40(3):42-4
145. Lundqvist G, Morgenstern R. Mechanism of activation of rat liver microsomal glutathione transferase by noradrenaline and xanthine oxidase. Biochem Pharmacol 1992;43(8):1725-8
146. Sies H, Graf P. Hepatic thiol and glutathione efflux under the influence of vasopressin, phenylephrine and adrenaline. Biochem J 1985;226(2):545-9
147. Mikhailova ON, Gulyaeva LF, Filipenko ML. Gene expression of drug metabolizing enzymes in adult and aged mouse liver: A modulation by immobilization stress. Toxicology 2005;210(2-3):189-96
148. Konstandi M, Kostakis D, Harkitis P, et al. Role of adrenoceptor-linked signaling pathways in the regulation of CYP1A1 gene expression. Biochem Pharmacol 2005;69:277-87
149. Jørgensen EH, Celander M, Goksøyr A, Iwata M. The effect of stress on toxicant-dependent cytochrome p450 enzyme responses in the Arctic charr (Salvelinus alpinus). Environ Toxicol Chem 2001;20(11):2523-9
150. Boissy A. Fear and fearfulness in animals. Q Rev Biol 1995;70(2):165-91
151. Curé M, Rolinat JP. Behavioral heterogeneity in Sprague-Dawley rats. Physiol Behav 1992;51(4):771-4
152. Prasad BM, Sorg BA, Ulibarri C, Kalivas PW. Sensitization to stress and psychostimulants. Involvement of dopamine transmission versus the HPA axis. Ann NY Acad Sci 1995;771:617-25
153. Spanagel R, Montkowski A, Allingham K, et al. Anxiety: A potential predictor of vulnerability to the initiation of ethanol self-administration in rats. Psychopharmacology (Berl) 1995;122(4):369-73
154. Flint M, McCarty K, Jenkins F, et al. Psychological stress accelerates the onset of tumour formation and alters the type and location of tumours in a DMBA mouse carcinogenesis model. Stress Health 2010;27(3):129-38
155. Konstandi M, Kostakis D, Johnson E, et al. Evidence of alpha2-adrenoceptor involvement in B[alpha]P induction processes of drug-metabolizing enzymes: The effect of stress. Eur J Drug Metab Pharmacokinet 1998;23:491-5
156. Niwa T, Tsutsui M, Kishimoto K, et al. Inhibition of drug-metabolizing enzyme activity in human hepatic cytochrome P450s by bisphenol A. Biol Pharm Bull 2000;23(4):498-501
157. Arinç E, Arslan S, Adali O. Differential effects of diabetes on CYP2E1 and CYP2B4 proteins and associated drug metabolizing enzyme activities in rabbit liver. Arch Toxicol 2005;79(8):427-33
158. Rentesi G, Antoniou K, Marselos M, et al. Early maternal deprivation-induced modifications in the neurobiological, neurochemical and behavioural profile of adult rats. Behav Brain Res 2013;244:29-37
159. Hay N. Interplay between FOXO, TOR, and Akt. Biochim Biophys Acta 2011;1813(11):1965-70